Replies to post #220835 on Avid Bioservices Inc (CDMO)

[MazelMan]

Tx for sharing. Alvaroc

Norfffffffff

Placebo ??? My arsy !

[iTrendz]

Nice news! 1.43 x 1.45

[biopharm]

"The phosphatidylserine (PS) signaling pathway is a very interesting target for modulating the immune system's response to cancer. We look forward to exploring the potential of PS-targeting agents alone and with other immune modulators that may lead to novel advances in cancer therapy," said Dr.
Wolchok.

Thanks for the update Alvaroc2 : )

------------------------------------------

It looks like Jedd Wolchok is finding PS Targeting much better than some of his old time Big Pharma passions...

Dr. Jedd D. Wolchok, MD, PhD

Combining the checkpoint antibodies ipilimumab (Yervoy) and nivolumab (formerly BMS-936558) led to deep tumor regression in approximately one-third of patients with advanced melanoma in an ongoing phase I study. Additionally, responses to the combination were quicker than those normally observed with immunotherapy. The data were presented Wednesday at an American Society of Clinical Oncology (ASCO) press conference held in advance of the 2013 ASCO Annual Meeting.

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=94223961

-------------------------------------------

Blood tests for cancer has been being worked on for quite some time already ..... even by Jedd Wolchok:

The Ludwig researchers recently discovered that patients with low levels of a sub-group of MDSCs were more likely to respond well to ipilimumab, an immunotherapy approved for the treatment of melanoma.

“This novel assay has the potential to become a valuable tool in the clinical development of immune therapy in cancer patients,” said Wolchok, director of the Ludwig Collaborative Laboratory at MSKCC and Chair of the Scientific Advisory Board at Serametrix.
...
...
...
in Dec 2013 he (Jedd Wolchok) is working with Alexander Lesokhin on a new blood test for cancer patients, measuring circulating MDSC's
...
...
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=106991396

-----------------------------------------

I am very much waiting for some AF types to make more of a fool of themselves, because now some important puzzle pieces are being brought together at the right time.

[north40000]

Finally, MSK and Dr. Wolchuk's lab make a PR appearance with respect to PPHM. Wolchok, and Old, are familiar names because of their roles as leaders in clinical trials on behalf of one or more of BMY/MEDX in metastatic melanoma---I have boxes of documents from that time frame prior to,and during, TO offer by BMY for MEDX.

One way or another, PPHM should become even more interesting to oncology peers and Wall Street.